Integra LifeSciences reported first-quarter revenues of $368.9 million, a 3.1% decrease compared to the prior year. GAAP earnings per diluted share were $(0.04), while adjusted earnings per diluted share were $0.55. The company updated its full-year 2024 revenue guidance to $1.672 to $1.687 billion, including the impact of the Acclarent acquisition.
Revenues declined by 3.1% on a reported basis, with organic revenue down by 2.5% compared to the previous year.
GAAP earnings per diluted share were $(0.04), while adjusted earnings per diluted share reached $0.55.
The acquisition of Acclarent, Inc. was completed on April 1, adding approximately $80 million to the full-year revenue guidance.
Full-year 2024 revenue guidance was updated to a range of $1.672 billion to $1.687 billion.
For the full year 2024, the Company is updating its revenue and adjusted EPS expectations to $1.672 to $1.687 billion and $3.01 to $3.11, respectively. For the second quarter 2024, the Company expects reported revenues in the range of $411 million to $416 million, and adjusted earnings per diluted share are expected to be in the range of $0.60 to $0.65.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance